Research Outsourcing Office, IMED Biotech Unit, AstraZeneca, 199 Liangjing Road, Building 2, Zhangjiang Hi-Tech Park, Shanghai 201203, China.
AsiaPac & Emerging Markets, IMED Biotech Unit, AstraZeneca, 199 Liangjing Road, Building 2, Zhangjiang Hi-Tech Park, Shanghai 201203, China.
Drug Discov Today. 2015 Jul;20(7):794-8. doi: 10.1016/j.drudis.2015.02.007. Epub 2015 Feb 17.
The pharmaceutical industry has responded to the declining research and development (R&D) productivity over the past decade by decreasing its cost base and outsourcing parts of drug research, with China increasingly being the preferred destination for such outsourced work. For this Focus article, we collected and analyzed data for 66 China-based nonclinical contract research organizations (CROs); approximately 60% of the companies were localized in the Yangtze River Delta cluster and another 20% within the Beijing cluster. Almost 25% of the companies offered services in discovery biology, the single largest service offering in the data set, with another 20% offering preclinical research (toxicology, pharmacology, and animal models) and approximately 15% offering pharmaceutical development. The biologics and pharmaceutical development services represent key future growth areas, with CROs showing an increasing appetite for risk-sharing partnerships.
在过去十年中，制药行业应对研发（R&D）生产力下降的方式是降低成本基础，并将部分药物研究外包出去，而中国越来越成为此类外包工作的首选目的地。对于这篇重点文章，我们收集和分析了 66 家中国非临床合同研究组织（CRO）的数据；大约 60%的公司位于长三角集群，另外 20%位于北京集群。近 25%的公司提供发现生物学服务，这是数据集中最大的单一服务，另有 20%提供临床前研究（毒理学、药理学和动物模型），约 15%提供药物开发。生物制剂和药物开发服务代表着未来的关键增长领域，CRO 表现出越来越强烈的风险分担伙伴关系的意愿。
